• Explore /
  • Poster
  • / S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX) and capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC).

S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX) and capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC).

Abstract Poster

Authors

null

Cynthia G. Leichman

New York Univ, New York, NY

Cynthia G. Leichman , Shannon L McDonough , Stephen R Smalley , Kevin G. Billingsley , Heinz-Josef Lenz , Matthew A. Beldner , Aram F. Hezel , Mario R. Velasco , Katherine A Guthrie , Charles David Blanke , Howard S. Hochster

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

NCT00686166

Citation

J Clin Oncol 33, 2015 (suppl; abstr 3516)

DOI

10.1200/jco.2015.33.15_suppl.3516

Abstract #

3516

Poster Bd #

8

Abstract Disclosures

Similar Posters

First Author: D. Helbling

First Author: Rong-Xin Zhang

First Author: Somnath Mukherjee

First Author: A. Dewdney